Rep. Cliff Bentz Buys Amgen Inc. (NASDAQ:AMGN) Shares

Representative Cliff Bentz (R-Oregon) recently bought shares of Amgen Inc. NASDAQ: AMGN. In a filing disclosed on July 09th, the Representative disclosed that they had bought between $1,001 and $15,000 in Amgen stock on June 6th. The trade occurred in the Representative's "CHARLES SCHWAB SEP-IRA" account.

Representative Cliff Bentz also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of Procter & Gamble NYSE: PG on 6/6/2025.

Amgen Stock Up 1.2%

Shares of NASDAQ AMGN traded up $3.53 during midday trading on Wednesday, hitting $309.22. The company's stock had a trading volume of 1,782,675 shares, compared to its average volume of 2,844,098. The business's fifty day simple moving average is $287.97 and its two-hundred day simple moving average is $290.04. The company has a debt-to-equity ratio of 8.70, a current ratio of 1.17 and a quick ratio of 0.88. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85. The firm has a market capitalization of $166.27 billion, a price-to-earnings ratio of 28.21, a price-to-earnings-growth ratio of 2.76 and a beta of 0.49.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical research company reported $4.90 EPS for the quarter, beating the consensus estimate of $4.18 by $0.72. The business had revenue of $8.15 billion during the quarter, compared to analyst estimates of $8.05 billion. Amgen had a net margin of 17.39% and a return on equity of 176.11%. The business's revenue for the quarter was up 9.4% compared to the same quarter last year. During the same quarter last year, the firm posted $3.96 earnings per share. On average, equities analysts predict that Amgen Inc. will post 20.62 EPS for the current year.

Analysts Set New Price Targets

Several analysts recently weighed in on the stock. Citigroup raised their target price on shares of Amgen from $300.00 to $305.00 and gave the company a "neutral" rating in a report on Tuesday. UBS Group raised their target price on shares of Amgen from $315.00 to $326.00 and gave the company a "neutral" rating in a report on Monday. William Blair reaffirmed an "outperform" rating on shares of Amgen in a report on Tuesday, June 24th. Erste Group Bank lowered shares of Amgen from a "strong-buy" rating to a "hold" rating in a research note on Thursday, May 8th. Finally, Cantor Fitzgerald reiterated a "neutral" rating and issued a $305.00 price target on shares of Amgen in a research note on Tuesday, June 24th. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $307.27.

Hedge Funds Weigh In On Amgen

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Wealth Preservation Advisors LLC acquired a new stake in shares of Amgen during the 1st quarter valued at approximately $25,000. First Pacific Financial lifted its position in shares of Amgen by 304.5% during the 1st quarter. First Pacific Financial now owns 89 shares of the medical research company's stock valued at $28,000 after acquiring an additional 67 shares during the period. CBIZ Investment Advisory Services LLC lifted its position in shares of Amgen by 1,214.3% during the 1st quarter. CBIZ Investment Advisory Services LLC now owns 92 shares of the medical research company's stock valued at $29,000 after acquiring an additional 85 shares during the period. Pinney & Scofield Inc. acquired a new stake in shares of Amgen during the 4th quarter valued at approximately $26,000. Finally, Activest Wealth Management lifted its position in shares of Amgen by 3,433.3% during the 1st quarter. Activest Wealth Management now owns 106 shares of the medical research company's stock valued at $33,000 after acquiring an additional 103 shares during the period. Institutional investors and hedge funds own 76.50% of the company's stock.

Insider Activity

In other news, SVP Rachna Khosla sold 1,500 shares of the stock in a transaction that occurred on Thursday, June 5th. The shares were sold at an average price of $289.68, for a total value of $434,520.00. Following the sale, the senior vice president directly owned 8,162 shares in the company, valued at $2,364,368.16. This represents a 15.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.76% of the company's stock.

About Representative Bentz

Cliff Bentz (Republican Party) is a member of the U.S. House, representing Oregon's 2nd Congressional District. He assumed office on January 3, 2021. His current term ends on January 3, 2027. Bentz (Republican Party) is running for re-election to the U.S. House to represent Oregon's 2nd Congressional District. He declared candidacy for the 2026 election. Cliff Bentz graduated from Regis High School in 1970. Bentz earned a degree in history and business from Eastern Oregon State College in 1974 and a J.D. from Lewis and Clark Law School in 1977. His career experience includes working as a partner with the Yturri, O'Kief, Rose, and Burnham law firm. Bentz served as a board member and the vice chair of Project Dove.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.